Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 130Recurrence 34Lymphoma, Follicular 28Lymphoma, Large B-Cell, Diffuse 27Lymphoma, Non-Hodgkin 23Neoplasms 13Lymphoma 13Lymphoma, Mantle-Cell 11Lymphoma, B-Cell, Marginal Zone 11Leukemia, Lymphocytic, Chronic, B-Cell 11Hematologic Diseases 5Neoplasms, Plasma Cell 4Myelodysplastic Syndromes 4Lymphoma, B-Cell 4Hematologic Neoplasms 4Neoplasm Metastasis 3Melanoma 3Leukemia, Myeloid, Acute 3Pyloric Stenosis, Hypertrophic 2Prostatic Neoplasms 2Paraproteinemias 2Ovarian Neoplasms 2Lymphoproliferative Disorders 2Lymphoma, T-Cell, Peripheral 2Leukemia-Lymphoma, Adult T-Cell 2Leukemia, B-Cell 2Leukemia 2Immunoproliferative Disorders 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2

Interventions

dacetuzumab 7blinatumomab 6Rituximab 5ibrutinib 3Cyclophosphamide 3venetoclax 2tetulomab tetraxetan lu-177 2ponatinib 2fludarabine 2ferric carboxymaltose 2cobomarsen 2Vorinostat 2Valganciclovir 2Lutetium 2Lenalidomide 2Ifosfamide 2Ganciclovir 2Everolimus 2Dexamethasone 2Bortezomib 2ruxolitinib 1pomalidomide 1pegaspargase 1ficlatuzumab 1epratuzumab 1enzalutamide 1durvalumab 1denileukin diftitox 1cirmtuzumab 1asparaginase erwinia chrysanthemi recombinant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoproliferative Disorders × Lenalidomide × Clear all
NCT02733042 2023-11-18

FUSION NHL 001

Celgene

Phase 1/2 Completed
106 enrolled 48 charts
LymphoidOther hematologic neoplasm

Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00525447 2014-10-09

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

Seagen Inc.

Phase 1 Completed
36 enrolled
LymphoidPlasma cell

Blood Coagulation Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡